Allex

desloratadine

The marketing authorisation for Allex has been withdrawn at the request of the marketing authorisation holder.

This EPAR was last updated on 31/12/2009 .

More detail is available in the summary of product characteristics

Product details

Publication details

Product information

31/12/2009  Allex -EMEA/H/C/000312

Contents

• Annex I - Summary of product characteristics
• Annex IIA - Manufacturing-authorisation holder responsible for batch release
• Annex IIB - Conditions of the marketing authorisation
• Annex IIIA - Labelling
• Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Antihistamines for systemic use

Therapeutic indication

Aerius is indicated for the relief of symptoms associated with:
- allergic rhinitis (see section 5.1)
- urticaria (see section 5.1)

Changes since initial authorisation of medicine

Initial marketing-authorisation documents